DaVita (DVA) – Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for DaVita (NYSE: DVA):

• 11/2/2026 – DaVita had its price target raised by UBS Group from $270.00 to $287.00. They now have a “buy” rating on the stock.
• 11/2/2026 – DaVita had its price target lowered by Barclays from $224.00 to $216.00. They now have an “equal weight” rating on the stock.
• 11/2/2026 – DaVita had its price target raised by TD Cowen from $220.00 to $228.00. They now have a “buy” rating on the stock.
• 10/31/2026 – DaVita was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/21/2026 – DaVita had its “buy” rating reaffirmed by TD Cowen.
• 10/17/2026 – DaVita was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/9/2026 – DaVita was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 9/26/2026 – DaVita was downgraded by Wall Street Zen from “buy” to “hold”.
• 9/24/2026 – DaVita was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.

DaVita Stock Down 3.6%

DVA traded down $6.65 during trading on Thursday, hitting $176.85. 311,941 shares of the company traded hands, compared to its average volume of 890,528. DaVita Inc. has a one year low of $101.00 and a one year high of $247.49. The stock’s fifty day moving average is $182.82 and its 200 day moving average is $179.73. The firm has a market cap of $11.12 billion, a P/E ratio of 13.02, a price-to-earnings-growth ratio of 0.45 and a beta of 0.87.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Thursday, October 29th. The company reported $3.82 EPS for the quarter, topping the consensus estimate of $3.57 by $0.25. The business had revenue of $3.58 billion for the quarter, compared to analyst estimates of $3.52 billion. DaVita had a net margin of 6.49% and a negative return on equity of 225.93%. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.51 earnings per share. On average, equities research analysts forecast that DaVita Inc. will post 14.66 EPS for the current fiscal year.

DaVita Inc. is a healthcare provider focused on kidney care. Its core business is operating outpatient dialysis centers that provide treatment and related services to people with chronic kidney failure. The company also offers home dialysis programs, provides dialysis services to patients in hospitals, and supports kidney care through services such as care coordination and education. DaVita primarily serves patients in the United States and also operates in international markets. Founded in 1994 as Total Renal Care, the company adopted the name DaVita in 2000.